Spontaneous Bacterial Peritonitis: Diagnosis and Management
Paracentesis criteria, empiric ceftriaxone, albumin infusion, and lifelong secondary prophylaxis in cirrhotic ascites
Executive Summary
S1. Pathophysiology and Epidemiology
Mechanism of Bacterial Translocation
SBP develops through a multi-step pathway in cirrhotic patients with portal hypertension and ascites:
- Small intestinal bacterial overgrowth (SIBO): Cirrhosis is associated with reduced gut motility, hypochlorhydria, and impaired bile acid secretion, leading to overgrowth of enteric bacteria.
- Intestinal barrier disruption: Portal hypertension causes intestinal venous congestion, edema, and increased permeability ("leaky gut"). Bacterial endotoxin and viable bacteria cross the intact mucosal barrier.
- Bacterial translocation to mesenteric lymph nodes: Bacteria reach mesenteric lymph nodes via lymphatic transport. In healthy persons, immune containment occurs here; in cirrhosis, impaired phagocytic function permits passage.
- Bacteremia and ascitic fluid seeding: Translocated bacteria reach systemic circulation via thoracic duct, then seed ascitic fluid through transudation across the visceral peritoneum.
- Failed local defense: Ascitic fluid in cirrhosis has reduced complement, low protein (<1 g/dL impairs opsonization), and impaired neutrophil function, allowing infection to establish.
Risk Factors for SBP Development
| Category | Risk Factors |
|---|---|
| Severity of liver disease | Child-Pugh C, MELD ≥18, total bilirubin >3 mg/dL, prothrombin time prolonged |
| Ascitic fluid characteristics | Total protein <1 g/dL (key risk factor; impaired opsonization); SAAG >1.1 g/dL (portal hypertensive ascites) |
| Prior SBP episode | 70% recurrence within 1 year without prophylaxis |
| Variceal hemorrhage | Up to 50% develop infection within 7 days; antibiotic prophylaxis (ceftriaxone or norfloxacin) is standard |
| Renal dysfunction | AKI, hepatorenal syndrome, hyponatremia (<130 mEq/L) |
| Proton pump inhibitor use | Increased SBP risk via gastric pH alteration and bacterial overgrowth (controversial; reduce or discontinue PPI in stable cirrhotic patients without firm indication) |
| Endoscopic procedures | Increased risk after sclerotherapy, banding, ERCP |
Pathogen Distribution
| Setting | Common Pathogens | Resistance Concerns |
|---|---|---|
| Community-acquired SBP | E. coli (40-60%), Klebsiella (10-15%), Enterococcus (5-10%), Streptococcus (5-10%), other gram-negatives | Generally susceptible to ceftriaxone |
| Healthcare-associated SBP | E. coli, Klebsiella with possible ESBL, Enterococcus, MSSA/MRSA, Pseudomonas (less common) | Variable resistance; broaden empiric coverage based on local antibiogram |
| Nosocomial SBP (>48h hospitalization) | ESBL Enterobacterales, Pseudomonas, Acinetobacter, MRSA, VRE, Candida | High MDR risk; carbapenem ± vancomycin; consider antifungal if Candida |
| Post-quinolone prophylaxis | Quinolone-resistant E. coli, gram-positive cocci (Streptococcus, Enterococcus) | Avoid quinolones empirically; broader gram-positive coverage often needed |
Epidemiology
SBP affects 10-30% of cirrhotic patients hospitalized with ascites, with annual incidence of 8-30% in outpatient cirrhotics with ascites. The disease has remained a major cause of cirrhotic mortality despite advances in antibiotic therapy. Outcomes have improved with earlier diagnosis (universal paracentesis in admitted ascites), prompt antibiotic administration, and routine albumin administration. However, in-hospital mortality remains 20-40%; 1-year mortality after first SBP episode is 50-70%; this reflects underlying cirrhosis severity rather than treatment failure.
S2. Clinical Presentation and Diagnostic Paracentesis
Symptoms and Signs
SBP presentation is often subtle in cirrhotic patients; classic peritoneal signs may be absent due to ascites distension and altered immune response. Maintain high suspicion in any decompensating cirrhotic with ascites:
| Presentation | Frequency |
|---|---|
| Fever (often low-grade) | 50-70% |
| Abdominal pain (often diffuse, mild) | 40-70% |
| Encephalopathy (new or worsening) | 30-50% |
| Worsening ascites or new diuretic resistance | 30-50% |
| Hypotension or sepsis presentation | 10-20% |
| Acute kidney injury | 30% develop during SBP course |
| Asymptomatic (detected on routine paracentesis) | 10-30% |
Indications for Diagnostic Paracentesis
Diagnostic paracentesis is mandatory in all cirrhotic patients admitted to hospital with ascites, regardless of symptoms. Additional indications:
- Any sign of infection: fever, leukocytosis, abdominal pain, encephalopathy
- New onset acute kidney injury or hepatorenal syndrome
- Variceal hemorrhage or any GI bleeding
- New onset or worsening hepatic encephalopathy
- Diuretic-resistant ascites or refractory ascites
- Pre-procedure (large-volume paracentesis, TIPS placement)
Paracentesis Technique
| Step | Detail |
|---|---|
| Site selection | Left lower quadrant preferred (safer than right; lateral to rectus muscle, 2 finger-breadths cephalad and medial to anterior superior iliac spine); use ultrasound guidance to confirm fluid pocket and avoid bowel/vessels |
| Coagulopathy considerations | Routine FFP/platelet correction NOT indicated for diagnostic paracentesis even with INR up to 8 or platelets as low as 19,000; bleeding rate <1% in cirrhotic patients; only correct if active bleeding develops |
| Sterile technique | Chlorhexidine prep, sterile drape, sterile gloves; use Z-track technique to prevent fluid leakage |
| Local anesthesia | 1-2% lidocaine to skin, subcutaneous tissue, and peritoneum (anticipate "give" as needle enters peritoneum) |
| Diagnostic sampling | Aspirate 30-50 mL ascitic fluid for analysis; large-volume paracentesis (>5 L) reserved for therapeutic indication |
| Bedside culture inoculation | 10 mL ascitic fluid into each of 2 blood culture bottles (aerobic + anaerobic) at the bedside immediately - increases yield from 40% (lab-only) to 70-80% |
Ascitic Fluid Analysis (Diagnostic Tests)
| Test | Normal in Cirrhotic Ascites | SBP Findings |
|---|---|---|
| PMN count (cells/μL) | <250 | ≥250 = diagnostic (gold standard regardless of culture); subtract 1 PMN per 250 RBCs if blood-tinged |
| Total WBC | Variable | Often elevated; less specific than PMN count |
| Culture (bedside-inoculated) | Negative | Positive in 40-60% of SBP; usually monomicrobial; gram-negative enterics common |
| Albumin (calculate SAAG = serum albumin - ascitic albumin) | SAAG >1.1 g/dL (portal HTN) | Unchanged by infection; useful for differential |
| Total protein | <1 g/dL (low) or higher | Low protein (<1 g/dL) is risk factor for SBP, NOT a diagnostic finding |
| Glucose | >50 mg/dL (similar to serum) | Glucose <50 mg/dL suggests SECONDARY peritonitis (perforation, abscess) |
| LDH | <225 IU/L (similar to serum upper limit) | LDH >225 IU/L (above serum normal) suggests secondary peritonitis |
| Gram stain | Negative | Positive gram stain suggests secondary peritonitis (high bacterial load); SBP gram stain usually negative due to low colony count |
| Cytology (if malignancy suspected) | Negative | Not part of SBP workup |
SBP Diagnostic Criteria Summary
Diagnostic Threshold
SBP is diagnosed when ascitic fluid PMN count is ≥250 cells/μL in the absence of an intra-abdominal source of infection. Treatment is initiated immediately based on PMN count alone, without waiting for culture results. Culture-negative neutrocytic ascites (CNNA: PMN ≥250 with negative culture) is treated identically to culture-positive SBP.Clinical Pearl - Bedside Inoculation Doubles Yield
The single most important technical step in SBP diagnosis is inoculating ascitic fluid directly into blood culture bottles AT THE BEDSIDE, not sending fluid in a tube to the lab. Bedside inoculation increases culture yield from 40% (lab-processed fluid) to 70-80% (bedside-inoculated). Use 10 mL into each aerobic and anaerobic blood culture bottle, immediately after fluid is withdrawn. This identifies the pathogen for targeted therapy and helps detect ESBL/MDR organisms requiring escalated coverage.Common Pitfall - Skipping Paracentesis Due to Coagulopathy
A frequent error is delaying or avoiding paracentesis in cirrhotic patients with elevated INR, low platelets, or low fibrinogen. Routine correction with FFP, platelets, or cryoprecipitate is NOT indicated for diagnostic paracentesis; bleeding complications occur in <1% even with INR >5 or platelets <50,000. The risk of missed SBP (mortality 20-40%) far exceeds the rare bleeding risk. Use ultrasound guidance, lateral approach, Z-track technique, and avoid sites with visible vessels - then proceed regardless of coagulation parameters.S3. Variants and Differential Diagnosis
SBP Variants
| Variant | PMN Count | Culture | Treatment |
|---|---|---|---|
| Classic SBP | ≥250/μL | Positive (monomicrobial) | Treat as SBP; tailor antibiotic to organism |
| Culture-Negative Neutrocytic Ascites (CNNA) | ≥250/μL | Negative | Treat as SBP (identical empiric regimen); represents true SBP with culture failure |
| Monomicrobial Non-Neutrocytic Bacterascites (MNB) | <250/μL | Positive (monomicrobial) | Repeat paracentesis: if symptomatic OR PMN now ≥250 OR same organism, treat as SBP; if asymptomatic and culture clears spontaneously, observe |
| Polymicrobial Bacterascites | <250/μL | Multiple organisms | Suspect bowel perforation from paracentesis needle; observe with serial paracentesis; rarely requires intervention |
Differential: Secondary Bacterial Peritonitis
Secondary peritonitis (perforation, abscess, gangrenous cholecystitis) requires surgical evaluation, not just antibiotics. Distinguishing from SBP is critical because mortality from missed surgical pathology approaches 100%.
| Feature | SBP | Secondary Peritonitis |
|---|---|---|
| PMN count | ≥250/μL | Often >1000/μL |
| Culture | Monomicrobial (40-60%) | Polymicrobial (mixed enteric flora) |
| Total protein | Variable; often low (<1 g/dL) | Often >1 g/dL |
| Glucose | >50 mg/dL (close to serum) | <50 mg/dL (consumed by bacteria) |
| LDH | | >serum upper limit | |
| Gram stain | Usually negative | Often positive with multiple morphologies |
| CEA, alkaline phosphatase | Normal | CEA >5 ng/mL OR alkaline phosphatase >240 IU/L (Runyon's criteria) |
| Clinical course | Improves with antibiotics 48h | No improvement; worsening despite antibiotics |
| Imaging | Normal (ascites only) | Free air, abscess, perforation, complicated obstruction |
Runyon's criteria for secondary peritonitis (≥2 of 3 = high suspicion):
- Total protein >1 g/dL
- Glucose <50 mg/dL
- LDH > upper limit of normal serum
Plus: CEA >5 ng/mL OR alkaline phosphatase >240 IU/L (highly specific for perforation). When secondary peritonitis is suspected: emergent abdominal CT with contrast, surgical consultation, broaden antibiotics (carbapenem + metronidazole + consider vancomycin), and source control intervention.
Other Differentials
| Condition | Distinguishing Features |
|---|---|
| Tuberculous peritonitis | Lymphocyte-predominant ascites (>40%); ADA >36-40 U/L; high SAAG <1.1 (exudative); PCR or culture for M. tuberculosis; chronic course; weight loss |
| Malignant ascites | SAAG <1.1 (exudate); high total protein >2.5 g/dL; cytology positive; CEA elevated; ascitic LDH high; cancer history |
| Pancreatic ascites | Ascitic amylase >1000 U/L; history of pancreatitis or pancreatic surgery; chronic pancreatitis with ductal disruption |
| Chylous ascites | Milky appearance; triglycerides >200 mg/dL; lymphatic obstruction (malignancy, surgery, lymphoma) |
| Cardiac ascites | SAAG ≥1.1 (transudate); high total protein >2.5 g/dL (CHF); echocardiogram shows reduced EF or restrictive physiology |
| Nephrogenic ascites | End-stage renal disease on dialysis; rare; transudate |
S4. Empiric Antibiotic Therapy and Albumin
Empiric Antibiotic Selection
| Setting | First-Line Regimen | Duration |
|---|---|---|
| Community-acquired SBP, no recent hospitalization, no quinolone prophylaxis | Ceftriaxone 2 g IV daily OR Cefotaxime 2 g IV q8h | 5 days (extended to 7-10 days if culture-proven gram-negative bacteremia or slow improvement) |
| Healthcare-associated SBP (hospitalized within 90 days, healthcare contact) | Piperacillin-tazobactam 4.5 g IV q8h OR Cefepime 2 g IV q8h + consider adding metronidazole if anaerobic risk | 5-7 days |
| Nosocomial SBP (developed >48h after admission) | Meropenem 1 g IV q8h + Vancomycin 25-30 mg/kg IV loading, then AUC-guided | 5-10 days; tailor to culture; consider antifungal if Candida |
| SBP on quinolone prophylaxis | Avoid quinolones empirically; use third-generation cephalosporin OR pip-tazo + add gram-positive coverage | 5-7 days |
| Severe sepsis or septic shock | Meropenem 1 g IV q8h + Vancomycin 25-30 mg/kg IV loading ± antifungal; ICU admission | 7-14 days; tailor to culture and clinical response |
| ESBL/CRE risk (prior colonization, MDR exposure) | Meropenem 1 g IV q8h for ESBL; Ceftazidime-avibactam 2.5 g IV q8h for CRE | 7-14 days; antimicrobial stewardship consultation |
| True beta-lactam allergy | Vancomycin + Aztreonam 2 g IV q8h; OR Vancomycin + Ciprofloxacin 400 mg IV q12h if no quinolone resistance | 5-7 days; consider desensitization for severe infection |
Antibiotic De-escalation
Once cultures return, narrow antibiotics to the most appropriate agent:
- Susceptible E. coli or Klebsiella → ceftriaxone 2 g IV daily for 5 days total
- ESBL E. coli or Klebsiella → ertapenem 1 g IV daily or meropenem 1 g IV q8h for 7-10 days
- Pseudomonas → cefepime 2 g IV q8h or pip-tazo 4.5 g IV q8h for 7-14 days
- Enterococcus faecalis → ampicillin 2 g IV q4h for 7-10 days
- Enterococcus faecium (often vancomycin-resistant) → daptomycin 8-10 mg/kg IV daily or linezolid 600 mg IV/PO q12h
- MRSA → vancomycin (AUC 400-600 mg·h/L) or daptomycin 8-10 mg/kg IV daily for 14 days
- Candida → fluconazole 800 mg IV loading, then 400 mg IV daily if susceptible; echinocandin if azole-resistant or critically ill
Albumin Infusion - Reduces HRS and Mortality
The landmark Sort et al. trial (NEJM 1999) showed that IV albumin reduced hepatorenal syndrome from 33% to 10% and 90-day mortality from 41% to 22% in SBP patients. Mechanisms include increased plasma oncotic pressure, splanchnic vasoconstriction, improved renal perfusion, and binding of inflammatory cytokines.
| Albumin Indication | Recommended Dose |
|---|---|
| Standard SBP (especially Cr >1, BUN >30, or bilirubin >4 mg/dL) | Day 1: Albumin 25% 1.5 g/kg IV (max 100 g) within 6 hours of diagnosis Day 3: Albumin 25% 1.0 g/kg IV (max 50 g) |
| All SBP patients (some guidelines including AASLD) | Same regimen regardless of renal/liver dysfunction; benefit demonstrated even in lower-risk subgroups |
| Hepatorenal syndrome AKI development | Albumin 1 g/kg/day day 1, then 25-50 g IV daily + vasoconstrictor (terlipressin, norepinephrine, or octreotide+midodrine) |
| Large-volume paracentesis (LVP) >5L | Albumin 6-8 g per liter ascitic fluid removed (separate indication, not for infection prevention) |
Reassessment at 48 Hours
Repeat paracentesis at 48 hours to assess treatment response:
- PMN count decreased by ≥25% from baseline → continue same antibiotic; expect clinical improvement
- PMN count not decreased ≥25% → consider treatment failure; broaden antibiotic coverage; reassess for secondary peritonitis (CT abdomen, surgical consultation); culture follow-up
- New positive culture for organism not covered → switch antibiotics
- Clinical deterioration → broaden coverage immediately, ICU evaluation, source control investigation
Avoid Aminoglycosides in SBP
Aminoglycosides (gentamicin, tobramycin, amikacin) should be avoided in cirrhotic SBP patients due to high nephrotoxicity risk in the setting of hepatorenal physiology. Aminoglycoside-induced AKI in cirrhotic patients can precipitate hepatorenal syndrome and rapidly fatal decline. Third-generation cephalosporins, piperacillin-tazobactam, and carbapenems achieve adequate coverage without renal toxicity. If aminoglycoside is unavoidable (severe MDR pseudomonas), use single daily dosing with strict therapeutic monitoring and restrict to shortest possible duration.S5. Hepatorenal Syndrome and Complications
Hepatorenal Syndrome - AKI (HRS-AKI)
HRS-AKI (formerly type 1 HRS) is a functional renal failure in cirrhosis characterized by intense renal vasoconstriction in response to splanchnic vasodilation and effective arterial underfilling. SBP precipitates HRS in up to 30% of cases despite albumin therapy. Without effective treatment, HRS-AKI carries 80-90% short-term mortality.
| Criterion (ICA-AKI 2015 Revised) | Detail |
|---|---|
| Diagnosis of cirrhosis with ascites | Required |
| AKI by ICA criteria | SCr increase ≥0.3 mg/dL within 48h, or ≥50% from baseline within 7 days |
| No improvement after 48h volume expansion | Albumin 1 g/kg IV daily (max 100 g/day) x 2 days + diuretic withdrawal |
| Absence of shock | Required (excludes prerenal azotemia from septic shock) |
| No nephrotoxic drugs | Discontinue NSAIDs, aminoglycosides, IV contrast |
| No structural kidney disease | Proteinuria <500 mg/day, no hematuria, normal renal ultrasound |
HRS-AKI Treatment
| Therapy | Dosing | Notes |
|---|---|---|
| Terlipressin (FDA approved 2022) | 1 mg IV q4-6h; titrate to 2 mg q4h if SCr does not decrease ≥25% in 3 days; max 12 mg/day | First-line per AASLD; reduces SCr in 30-50%; avoid if hypoxia (CONFIRM trial showed respiratory failure risk in advanced lung disease) |
| Albumin (concurrent with vasoconstrictor) | 1 g/kg day 1 (max 100g), then 25-50 g/day IV | Continue throughout vasoconstrictor course; do not exceed CVP-guided fluid status |
| Norepinephrine (alternative to terlipressin) | 0.5-3 mg/hr IV titrated to MAP increase 10 mmHg | ICU setting required; acceptable alternative; equivalent efficacy in some studies |
| Octreotide + Midodrine + Albumin (where terlipressin unavailable) | Octreotide 100-200 mcg SC q8h + Midodrine 7.5-12.5 mg PO q8h + Albumin | Less effective than terlipressin; reasonable bridge in non-ICU settings |
| Renal replacement therapy | CRRT or intermittent HD as needed | Bridge to transplant; not definitive therapy |
| Liver transplantation | Listing prioritized for HRS | Only definitive therapy; HRS reversal does not eliminate transplant need; combined liver-kidney transplant if HRS sustained >4-8 weeks despite therapy |
Other SBP Complications
| Complication | Frequency | Management |
|---|---|---|
| Hepatic encephalopathy | 30-50% | Lactulose 20-30 g PO/PR q1-2h to BMs, then 15-30 g PO q6-8h; rifaximin 550 mg PO BID for refractory; treat precipitant (SBP itself) |
| Variceal hemorrhage | 10-20% | Octreotide 50 mcg IV bolus, then 50 mcg/hr infusion x 5 days; emergent endoscopy with band ligation; consider TIPS for refractory bleeding |
| Septic shock | 5-15% | Aggressive fluid resuscitation (crystalloid + albumin), norepinephrine first-line, vasopressin add-on, broad-spectrum antibiotics, ICU admission; mortality >50% |
| Pleural effusion (hepatic hydrothorax) | Variable | Diuretics; thoracentesis if symptomatic; avoid chest tube (risk of fluid loss, infection); TIPS for refractory cases |
| Adrenal insufficiency | 30-50% in critically ill cirrhotics | Hydrocortisone 200 mg/day IV (50 mg q6h or continuous infusion) in septic shock with vasopressor requirement |
| Acute-on-chronic liver failure (ACLF) | Common precipitant | Supportive care; transplant evaluation urgent if ACLF grade 2-3; mortality 30-90% depending on grade |
SBP as Sentinel Event for Transplant Evaluation
First episode of SBP carries 1-year mortality of 50-70%, regardless of treatment success of the acute infection. SBP marks a transition to advanced cirrhosis with substantially worse prognosis. All patients surviving SBP should undergo expedited liver transplantation evaluation if not already listed: confirm MELD-Na score, evaluate for transplant contraindications (active alcohol/substance use, severe pulmonary HTN, uncontrolled HCC, severe cardiac/pulmonary disease), and place patient on transplant list as soon as eligibility confirmed. Time on the list and MELD score guide priority. SBP itself does not earn MELD exception points but signals advanced disease requiring urgent evaluation.S6. Prophylaxis and Long-term Management
Secondary SBP Prophylaxis (After First Episode)
All patients who survive an SBP episode should receive lifelong secondary prophylaxis (or until liver transplantation). Without prophylaxis, recurrence rate is 70% within 1 year. With prophylaxis, recurrence falls to <20%.
| Antibiotic | Dose | Notes |
|---|---|---|
| Norfloxacin (preferred where available) | 400 mg PO daily | Most evidence; selective gut decontamination of gram-negatives; first-line per AASLD/EASL |
| Ciprofloxacin | 500 mg PO daily OR 750 mg PO weekly | Alternative; daily dosing more effective than weekly in trials |
| Trimethoprim-sulfamethoxazole | 1 DS tab (160/800 mg) PO daily | Alternative for quinolone-allergic or quinolone-resistant settings; monitor for hyperkalemia and renal function |
| Rifaximin | 550 mg PO BID | Emerging evidence; reduces SBP and HE recurrence in some studies; not yet first-line for SBP prophylaxis alone |
Primary SBP Prophylaxis (Without Prior SBP)
Primary prophylaxis is indicated for high-risk patients who have NEVER had SBP but have:
- Ascitic fluid total protein <1.5 g/dL AND
- At least one of:
- Renal dysfunction: SCr ≥1.2 mg/dL, BUN ≥25 mg/dL, or sodium ≤130 mEq/L
- Advanced liver failure: Child-Pugh ≥9 points with bilirubin ≥3 mg/dL
Primary prophylaxis regimen: norfloxacin 400 mg PO daily (or alternative). Continue until ascites resolves, transplantation, or death.
Variceal Hemorrhage Prophylaxis
All cirrhotic patients with variceal or non-variceal upper GI bleeding require antibiotic prophylaxis from admission for 7 days, regardless of ascites or prior SBP. Bacterial infection complicates 50% of cirrhotic GI bleeds within 7 days.
| Patient Setting | Antibiotic |
|---|---|
| Decompensated cirrhosis (Child-Pugh B/C, advanced disease) | Ceftriaxone 1 g IV daily x 7 days |
| Compensated cirrhosis (Child-Pugh A) | Norfloxacin 400 mg PO BID x 7 days |
Lifestyle and Medical Management
| Recommendation | Detail |
|---|---|
| Sodium restriction | 2 g (88 mEq) sodium per day; central to ascites management |
| Fluid restriction | 1-1.5 L/day if serum sodium <130 mEq/L |
| Alcohol abstinence | Mandatory; consider naltrexone or acamprosate; avoid disulfiram in liver failure |
| Diuretic management | Spironolactone 100 mg PO daily, titrate to 400 mg + Furosemide 40 mg PO daily, titrate to 160 mg (100:40 ratio); hold diuretics during AKI |
| Beta-blockers (variceal prophylaxis) | Carvedilol 6.25-12.5 mg PO BID or nadolol 40-80 mg PO daily; controversial in refractory ascites and SBP - hold if hypotensive (SBP <90), AKI, or active SBP per "window hypothesis" |
| PPI use | Reassess indication; discontinue if no firm indication (PPI use associated with SBP and C. difficile) |
| Vaccinations | Influenza annually; pneumococcal (PCV15 then PPSV23); hepatitis A and B; COVID-19; do not use live vaccines in advanced cirrhosis |
| HCC surveillance | Ultrasound + AFP every 6 months in cirrhotic patients |
| Liver transplant evaluation | Initiate at diagnosis of any SBP; MELD-Na monitoring |
When to Refer for Hepatology and Liver Transplantation
Hepatology/transplant referral is appropriate for: (1) any first SBP episode; (2) recurrent SBP despite prophylaxis; (3) hepatorenal syndrome (HRS-AKI or HRS-NAKI); (4) refractory ascites requiring large-volume paracentesis >2 times monthly; (5) MELD-Na ≥15 (transplant evaluation threshold); (6) hepatic encephalopathy episodes requiring hospitalization; (7) variceal hemorrhage; (8) HCC diagnosis; (9) consideration of TIPS for refractory ascites or variceal bleeding. Outpatient follow-up: hepatology within 2 weeks of SBP discharge for prophylaxis verification, MELD calculation, and transplant evaluation initiation; gastroenterology for variceal surveillance per recommended interval (1-2 years if no varices, annually if small varices, at hemorrhage prophylaxis if medium-large).Long-term Outcomes
| Outcome | Without Transplant | With Transplant |
|---|---|---|
| Survival 30 days post-SBP | 70-80% | 95%+ (if transplanted before next decompensation) |
| Survival 1 year post-SBP | 30-50% | 85-90% |
| Survival 5 years post-SBP | 15-25% | 70-80% |
| SBP recurrence (no prophylaxis) | 70% in 1 year | — |
| SBP recurrence (with prophylaxis) | 15-25% in 1 year | — |
| HRS development after SBP | 30% (10% with albumin) | — |
Clinical Pearl - Beta-Blocker Window Hypothesis
The traditional teaching that all cirrhotics on non-selective beta-blockers (carvedilol, nadolol, propranolol) for variceal prophylaxis should remain on them indefinitely has been challenged. The "window hypothesis" suggests beta-blockers benefit compensated cirrhotics but may worsen outcomes in advanced disease (refractory ascites, SBP, HRS, hypotension) by impairing cardiac output reserve. Current AASLD guidance: hold or discontinue beta-blockers if SBP <90 mmHg, AKI, hyponatremia <120, or active SBP. Reassess after recovery; restart cautiously at lower dose if hemodynamically tolerated.Common Pitfall - Inadequate Albumin Dosing
A frequent error is omitting or underdosing albumin in SBP, particularly in patients without obvious renal dysfunction or jaundice. The Sort trial showed albumin reduces 90-day mortality from 41% to 22% across SBP patients; benefit is greatest in those with Cr >1, BUN >30, or bilirubin >4, but mortality benefit extends to lower-risk groups. Use the full dose: 1.5 g/kg on day 1 within 6 hours of diagnosis (not over multiple days), and 1 g/kg on day 3. Common errors include using 5% albumin (use 25%), splitting the day 1 dose over 24 hours (give as bolus or short infusion), or omitting day 3 dose.S7. Practice Insights: Bedside Notes on SBP
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Death in spontaneous bacterial peritonitis usually arrives through renal failure rather than through the infection itself — SBP's mortality is set by three things: time-to-paracentesis at admission, day-1 albumin infusion, and recognizing secondary bacterial peritonitis early enough to operate. In experienced hands the pivot points are paracentesis on EVERY cirrhotic admission with ascites (not just those with abdominal symptoms), albumin 1.5 g/kg day 1 + 1.0 g/kg day 3 (no negotiation), and Runyon criteria assessment to distinguish primary SBP from secondary that needs surgery. Seasoned clinicians track three things during management: PMN trajectory (repeat para if clinical doubt at 48h), creatinine (HRS prevention is the goal), and cefotaxime susceptibility from culture.
What the Guideline Misses — Paracentesis on EVERY Cirrhotic Admission
Diagnostic paracentesis is mandated at admission by guidelines but in experienced practice this is the most commonly skipped intervention. Atypical presentations (no fever, no abdominal pain — just confusion or AKI in cirrhotic) hide SBP. About 1 in 6 of the SBP cases had no classic symptoms; the diagnosis came from routine admission paracentesis. clinicians order paracentesis as part of the admission order set for any cirrhotic patient with ascites.
Patterns That Repeat in Practice — Albumin Day 1 + Day 3 Saves Kidneys
Sort et al 1999 trial showed albumin 1.5 g/kg day 1 + 1.0 g/kg day 3 cuts HRS by ~60% and mortality meaningfully. In practice this is hard-wired into the SBP order set — neither dose negotiable. The day-3 dose is the one most frequently forgotten by floor teams. Experienced practitioners round on this every day-3 morning to make sure it goes in.
Secondary Peritonitis Detection
Secondary bacterial peritonitis (perforated viscus, abscess) has high mortality if treated as SBP. Runyon criteria for SBP: ascitic fluid glucose <50 mg/dL + protein >1 g/dL + LDH > ULN serum (2 of 3 = secondary likely). Polymicrobial culture or anaerobes or fungi also suggest secondary. CT abdomen and surgical consultation are mandatory. About 1 in 20 of the "SBP" workups turn out to be secondary — surgery saves lives.
Bedside Heuristic — Repeat Paracentesis at 48 Hours
If clinical improvement is ambiguous or the patient remains febrile/encephalopathic at 48 hours, clinicians repeat paracentesis. PMN drop ≥25% from baseline confirms response; failure to drop triggers broader-spectrum coverage and CT imaging for secondary peritonitis. About 1 in 8 of the SBP cases require regimen change based on 48h paracentesis; without it clinicians would have continued ineffective therapy.
A Case That Reframed The Approach — Secondary Peritonitis Almost Missed
A man in his late 50s with Child C cirrhosis admitted with fever, encephalopathy, and ascites. Admission paracentesis: PMN 850, culture growing Klebsiella + E. coli + Bacteroides (polymicrobial). Started cefotaxime + albumin. By hour 48 he was deteriorating: fever persistent, lactate rising, new RLQ tenderness. Repeat paracentesis: PMN 1800 (worse); fluid analysis ascitic glucose 35, protein 2.4, LDH 380 (serum ULN 250). All three Runyon criteria met → secondary peritonitis suspected. CT abdomen showed perforated diverticulum with abscess. Surgery, drainage, expanded antibiotics (pip-tazo + metro). He survived but required prolonged ICU stay. What clinicians learned: polymicrobial growth + Runyon criteria positivity is a surgical emergency. The treating clinicians now check Runyon criteria on every SBP fluid analysis, not just "concerning" cases.
Practice Pattern Refinements That Diverge From Standard Guidelines
- Diagnostic paracentesis on EVERY cirrhotic admission with ascites — built into admission order set. Don't wait for "fever or abdominal pain." About 1 in 6 SBP cases present atypically. The paracentesis is low-risk; missing SBP is high-mortality.
- Albumin 1.5 g/kg day 1 + 1.0 g/kg day 3 — hard-wired in order set with day-3 reminder. Both doses non-negotiable. The day-3 dose gets forgotten most often. Experienced clinicians literally round on day 3 to verify it gets administered.
- Full Runyon criteria on every ascitic fluid (glucose + protein + LDH) — not just cell count. Standard ordering is cell count + culture. clinicians add glucose, protein, LDH on every fluid to screen for secondary peritonitis. The cost is trivial; the diagnostic miss is fatal.
- Repeat paracentesis at 48h if clinical doubt — confirm ≥25% PMN drop. Clinical assessment alone misses non-responders. The 48h repeat para catches both treatment failure (resistant organism, secondary peritonitis) and overcautious teams who would have escalated unnecessarily.
Frequently Asked Questions
- Liver Cirrhosis — Diagnosis and Complications Management
- Crohn Disease — Diagnosis and Therapeutic Management
- Barrett Esophagus: Diagnosis, Surveillance, and Management
- Eosinophilic Esophagitis: Diagnosis, Treatment, and Monitoring
- Gastroparesis: Diagnosis, Prokinetic Therapy, and Management
- NAFLD and MASLD: Diagnosis, Risk Stratification, and Management
Primary guideline documents this article draws on. Links resolve via DOI to the publisher; access may require a subscription.
- AASLD 2021 Guidance: ascites, SBP and hepatorenal syndrome in cirrhosis (Hepatology · 2021)